By Dorothy Atkins ( July 11, 2016, 4:32 PM EDT) -- Lipocine Inc. misled investors by saying the U.S. Food and Drug Administration cleared its new testosterone drug when in fact the agency identified issues with the labeling, causing stock values to plummet, according to a putative class action filed in New Jersey federal court Friday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.